Supply Issues Bayer PLC Contrast Media Injector Options JAH418 and JAH419 (ICN 2522)

Change:

• The supplier Bayer PLC has informed us of a supply issue with its Contrast Media Injector Options products.
• The two product codes affected are:
  • JAH418- Arterion twist & go high pressure connecting tube 120cm (48 inch)- non-Returnable
  • JAH419- Arterion twist & go high pressure connecting tube 150cm (60 inch)- non-Returnable.
• The supply issue is due to supplier manufacturing issues.

Impact:          

• The affected codes are currently unavailable to order.
• Unfortunately, there are no alternatives available. Customers are advised to view the online catalogue for products they deem suitable.
• We are currently sourcing further alternatives and updates will be made to the product listing as soon as possible.
• See our Downloads ▼ section to access the product listing for further information on the affected product codes and the customer letter.
• The supply issue is anticipated to be resolved by 25 July 2024.

Next Steps:              

• Customers are advised to log into our website to view the product listing for further information on the affected product codes.
• Tubing should be sterile, high pressure rated (Arterion injectors have a maximum pressure limit of 1200psi) and should have male and female luer connections. Lines can be chosen based on a suitable length as desired by the user.
• The continuing supply issue is being monitored in conjunction with the supplier and we will continue to review the stock situation to minimise further disruption and update this ICN with the latest information as it becomes available.
• However, as this is currently a disrupted market and supply is subject to rapid change, the alternatives offered may also be experiencing temporary supply issues and therefore, customers may need to consider clinically reviewing all additional alternatives provided.
• If you have any further questions, please contact your local NHS Supply Chain Customer Services Advisor.

Please note that due to the clinical nature of these alternative products, we advise you to consult your own clinical experts to ensure suitability for your organisations use of these products.